Highly effective CFTR modulator therapy, including Elexacaftor/Tezacaftor/Ivacaftor (ETI), has been found to reduce significantly upper and lower respiratory symptoms and is approved for up to 90% of adults with CF genetic disorders [10,11,12]. Here, CFTR is linked to cystic fibrosis.